| P/E (FY) | — | Sales (TTM) | — |
| Earnings (TTM) | -$78.3M | ROE | −55.37% |
| Net Margin | — | ROIC | −67.45% |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
| Market Cap | $58.7M | Trading Days | 1359 |
| 52W High | 1.88 |
| 52W Low | 1.02 |
| % Off High | −41.49% |
| YTD | −12.00% | 1Y | −27.15% |
| 3Y | −83.70% | 5Y | −96.92% |
| Since incept. (ann.) | −48.65% |
| Ann. Volatility (1Y) | 71.19% | Ann. Volatility (3Y) | 78.38% |
| Sharpe (1Y) | −0.11 | Sharpe (3Y) | −0.34 |
| Max Drawdown (1Y) | −41.11% | Max Drawdown (3Y) | −90.61% |
| Beta (3Y, vs SPY) | 2.25 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| ANVS | Annovis Bio, Inc. | $58.6M | — |
| CING | Cingulate Inc. | $60.1M | — |
| ELTX | Elicio Therapeutics, Inc. | $56.3M | — |
| RFL | Rafael Holdings, Inc. | $61.8M | — |
| BOLD | Boundless Bio, Inc. | $55.5M | — |
| LIXT | LIXTE BIOTECHNOLOGY HOLDINGS, INC. | $55.1M | — |
| CNTX | Context Therapeutics Inc. | $54.3M | — |
| RANI | Rani Therapeutics Holdings, Inc. | $54.2M | — |
| HYFT | MindWalk Holdings Corp. | $63.5M | — |
| CLNN | Clene Inc. | $63.8M | — |
| XLO | Xilio Therapeutics, Inc. | $52.9M |
| — |
| CPHI | CHINA PHARMA HOLDINGS, INC. | $52.7M | — |
